Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (999)	4/21/1999 8:26:00 PM
From: Rocketman	Respond to of 3202

Yeah, they do sound pretty good. INCY has needed a good point person for the Pharma customers. And for the tech devo, Richard Johnston sounds pretty good. I don't see this press release on Yahoo now though, I wonder what happened to it? Rman

To: scaram(o)uche who wrote (999)	4/21/1999 8:36:00 PM
From: Rocketman	Read Replies (2) \| Respond to of 3202

Good news and bad news on the Q results: biz.yahoo.com The good news is the loss for the Q is only $0.07 per share, which is a lot better than the $0.14 per share whisper number loss. The bad news is that they cut revenue projection for the year from $190M to $170-175M. The good news is that they say that the loss for the year will still be $20M even with the lower revenue. The bad news is that CFO Denise Gilbert is going for a bike ride. biz.yahoo.com The good news is that she was in charge of the investor relations department, so maybe we will see some improvement here. I really appreciate that they included the following update on patents in the Q press release (way to go Dana! We know you are lurking out there @;-). Hopefully we will be seeing these updates on a quarterly basis. They really provide some basis for looking at the sequencing trends. <<<<<<< Incyte was issued 66 new U.S. patents covering full-length genes during the first quarter, bringing the total to over 200 full-length gene patents issued to the Company. Incyte has also received notices of allowance on patents covering an additional 195 full-length genes and has to date filed patent applications covering approximately 3,300 full-length genes. >>>>>>> More good news is the two new key hires that Rick posted about previously. Rick, what is your take on the impact of the MegaBace loss to PKN on the patent issues, and its potential impact on INCY? Rman